文献速递肿瘤 PET/CT核素与放射性配体治疗

新诊断前列腺癌疑似区域淋巴结转移患者的前列腺特异性膜抗原靶向放射性引导盆腔淋巴结清扫:DETECT试验

Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
PubMed 文献 · J Nucl Med · 2024-03-01

这项前瞻性I/II期研究纳入20例术前18F-PSMA PET/CT提示至少1枚可疑淋巴结的新诊断前列腺癌患者,评估111In-PSMA放射性引导手术的安全性和可行性。结果显示无示踪剂相关不良事件,49枚可疑病灶中43枚(88%)成功切除,111In-PSMA RGS术中识别并切除29枚靶病灶,其中28枚(97%)含淋巴结转移。结论认为该操作安全可行,可能改善术中识别和切除可疑淋巴结。

要点

  • 111In-PSMA放射性引导手术在20例新诊断前列腺癌患者中未报告示踪剂相关不良事件。
  • 49枚18F-PSMA PET/CT可疑病灶中43枚(88%)成功切除。
  • 111In-PSMA RGS术中识别并切除29枚靶病灶,其中28枚(97%)含淋巴结转移。

核心结论

  • 111In-PSMA RGS是安全可行的操作,可在新诊断前列腺癌患者术中检测18F-PSMA PET/CT提示的可疑病灶。
  • 术中使用放射性PSMA示踪剂和γ探测仪有助于识别术前18F-PSMA PET/CT提示前列腺癌转移的淋巴结,从而可能改善术中识别和切除这些淋巴结。

研究设计与样本

  • 前瞻性I/II期研究,纳入20例新诊断前列腺癌患者,术前18F-PSMA PET/CT至少1枚可疑淋巴结。
  • 给予111In-PSMA-I&T后24小时行PSMA RGS,术后行18F-PSMA PET/CT验证可疑病灶是否成功切除。
  • 主要终点为111In-PSMA RGS的安全性和可行性,安全性通过监测不良事件评估,可行性定义为术中检测术前影像提示可疑淋巴结的可能性。
  • 次要结局包括111In-PSMA RGS与组织病理学相比的准确性、肿瘤和病灶本底比及生化复发。

主要发现

  • 未报告示踪剂相关不良事件。
  • 20例患者中,49枚18F-PSMA PET提示病灶有43枚(88%)成功切除。
  • 111In-PSMA RGS帮助术中识别并切除49枚RGS靶病灶中的29枚(59%),其中28枚(97%)含淋巴结转移。
  • 另有14枚(29%)切除淋巴结未被111In-PSMA RGS检测到,其中2枚含转移。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) aims to optimize the peroperative detection and removal of PSMA-avid lymph node (LN) metastases (LNMs) and has been described in patients with recurrent prostate cancer (PCa). In newly diagnosed PCa patients undergoing pelvic LN dissections, PSMA RGS could guide the urologist toward PSMA-expressing LNMs as identified on preoperative 18F-PSMA PET/CT imaging. The objective was to evaluate the safety and feasibility of 111In-PSMA RGS in primary PCa patients with one or more suggestive LNs on preoperative 18F-PSMA PET/CT. Methods: This prospective, phase I/II study included 20 newly diagnosed PCa patients with at least 1 suggestive LN on preoperative 18F-PSMA PET/CT. PSMA RGS was performed 24 h after 111In-PSMA-I&T administration, and postoperative 18F-PSMA PET/CT was performed to verify successful removal of the suggestive lesions. The primary endpoint was determination of the safety and feasibility of 111In-PSMA RGS. Safety was assessed by monitoring adverse events. Feasibility was described as the possibility to peroperatively detect suggestive LNs as identified on preoperative imaging. Secondary outcomes included the accuracy of 111In-PSMA RGS compared with histopathology, tumor- and lesion-to-background ratios, and biochemical recurrence. Results: No tracer-related adverse events were reported. In 20 patients, 43 of 49 (88%) 18F-PSMA PET-suggestive lesions were successfully removed. 111In-PSMA RGS facilitated peroperative identification and resection of 29 of 49 (59%) RGS-target lesions, of which 28 (97%) contained LNMs. Another 14 of 49 (29%) resected LNs were not detected with 111In-PSMA RGS, of which 2 contained metastases. Conclusion: 111In-PSMA RGS is a safe and feasible procedure that allows peroperative detection of 18F-PSMA PET/CT-suggestive lesions in newly diagnosed PCa patients. The use of a radioactive PSMA tracer and a detection device (γ-probe) during surgery helps in identifying LNs that were suggestive of PCa metastases on the 18F-PSMA PET/CT before surgery and thus may improve the peroperative identification and removal of these LNs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schilham MGM, Somford DM, Küsters-Vandevelde HVN, et al. Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial. J Nucl Med. 2024. PMID: 38176721. doi:10.2967/jnumed.123.266495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。